Armistice Capital Performance: Strategic Investments in Biotechnology’s Rare Disease Frontier
The landscape of biotechnology investments continues to evolve with remarkable complexity, presenting a nuanced narrative of scientific innovation and financial strategy. Despite a significant decline...